Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models

Journal of the National Cancer Institute

Volumn 95, Issue 21, 2003, Pages 1624-1633

  Chung, Yuen Li ^a   Troy, Helen ^a   Banerji, Udai ^b   Jackson, Laura E ^b   Walton, Mike I ^b   Stubbs, Marion ^a   Griffiths, John R ^a   Judson, Ian R ^b   Leach, Martin O ^b   Workman, Paul ^b   Ronen, Sabrina M ^b  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLYAMINO,17 DEMETHOXYGELDANAMYCIN; ANSAMYCIN DERIVATIVE; ANTINEOPLASTIC AGENT; BIOCHEMICAL MARKER; CYTOTOXIC AGENT; DRUG METABOLITE; DRUG VEHICLE; ESTER DERIVATIVE; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HERBIMYCIN; ONCOPROTEIN; PHOSPHOETHANOLAMINE; PHOSPHOLIPID; PHOSPHORYLCHOLINE; PROTEASOME; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; VALINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER CELL CULTURE; COLON CANCER; CONTROLLED STUDY; DRUG MECHANISM; DRUG RESPONSE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NUDE MOUSE; PHARMACODYNAMICS; PHOSPHOLIPID METABOLISM; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTON NUCLEAR MAGNETIC RESONANCE; RANK SUM TEST; STATISTICAL SIGNIFICANCE; TUMOR XENOGRAFT; WESTERN BLOTTING;

EID: 0344393470     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djg084     Document Type: Article

References (55)

1. Workman P. Scoring a bull's-eye against cancer genome targets. Curr Opin Pharmacol 2001;1:342-52.
2. Workman P, Kaye SB. Translating basic cancer research into new cancer therapeutics. Trends Mol Med 2002;8(4 Suppl):S1-9.
3. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
4. Maloney A, Workman P. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther 2002;2:3-24.
5. Neckers L. Hsp90 inhibitions as novel cancer chemotherapeutic agents. Trends Mol Med 2002;8(4 Suppl):S55-61.
6. Neckers L, Schulte TW, Mimnaugh E. Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity. Invest New Drugs 1999;17:361-73.
7. Schulte TW, Neckers LM. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 1998; 42:273-9.
8. Supko JG, Hickman RL, Grever MR, Malspeis L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 1995;36:305-15.
9. Munster PN, Marchion DC, Basso AD, Rosen N. Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 over-expression via a HER3, phosphatidylinositol 3′-kinase-AKT-dependent pathway. Cancer Res 2002;62:3132-7.
10. Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P. DT-Diaphorase expression and tumor cells sensitivity to 17-allylamino,17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 1999;91:1940-9.
11. Clarke PA, Hostein I, Banerji U, Stefano FD, Maloney A, Walton M, et al. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Oncogene 2000;19:4125-33.
12. Hostein I, Robertson D, DiStefano F, Workman P, Clark PA. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res 2001;61:4003-9.
13. Workman P. Challenges of PK/PD measurements in modern drug development. Eur J Cancer 2002;38:2189-93.
14. Argov Z, Lofberg M, Arnold DL. Insights into muscle diseases gained by phosphorus magnetic resonance spectroscopy. Muscle Nerve 2000; 23:1316-34.
15. Arnold DL, De Stefano N. Magnetic resonance spectroscopy in vivo: applications in neurological disorders. Ital J Neurol Sci 1997;18:321-9.
16. Ingwall JS. Phosphorus nuclear magnetic resonance spectroscopy of cardiac and skeletal muscles. Am J Physiol 1982;242:H729-44.
17. Robinson SP, Barton SJ, McSheehy PM, Griffiths JR. Nuclear magnetic resonance spectroscopy of cancer. Br J Radiol 1997;70 Spec No:S60-9.
18. Daly PF, Cohen JS. Magnetic resonance spectroscopy of tumors and potential in vivo clinical applications: a review. Cancer Res 1989;49: 770-9.
19. Griffiths JR, McSheehy PM, Robinson SP, Troy H, Chung YL, Leek RD, et al. Metabolic changes detected by in vivo magnetic resonance studies of HEPA-1 wild-type tumors and tumors deficient in hypoxia-inducible factor-1beta (HIF-1beta): evidence of an anabolic role for the HIF-1 pathway. Cancer Res 2002;62:688-95.
20. Ronen SM, DiStefano F, McCoy CL, Robertson D, Smith TA, Al-Saffar NM, et al. Magnetic resonance detects metabolic changes associated with chemotherapy-induced apoptosis. Br J Cancer 1999;80:1035-41.
21. Leach MO, Verrill M, Glaholm J, Smith TA, Collins DJ, Payne GS, et al. Measurements of human breast cancer using magnetic resonance spectroscopy: a review of clinical measurements and a report of localized 31P measurements of response to treatment. NMR Biomed 1998;11:314-40.
22. Aboagye EO, Dillehay LE, Bhujwalla ZM, Lee DJ. Hypoxic cell cytotoxin tirapazamine induces acute changes in tumor energy metabolism and pH: a 31P magnetic resonance spectroscopy study. Radiat Oncol Investig 1998; 6:249-54.
23. Griffiths JR, Tate AR, Howe FA, Stubbs M. Magnetic resonance spectroscopy of cancer-practicalities of multi-centre trials and early results in non-Hodgkin's lymphoma. Eur J Cancer 2002;38:2085-93.
24. McSheehy PM, Seymour MT, Ojugo AS, Rodrigues LM, Leach MO, Judson IR, et al. A pharmacokinetic and pharmacodynamic study in vivo of human HT29 tumours using 19F and 31P magnetic resonance spectroscopy. Eur J Cancer 1997;33:2418-27.
25. United Kingdom Co-ordinating Committee on Cancer Research (UKC-CCR) guidelines for the welfare of animals in experimental neoplasia (second edition). Br J Cancer 1998;77:1-10.
26. Tyagi RK, Azrad A, Degani H, Salomon Y. Simultaneous extraction of cellular lipids and water-soluble metabolites: evaluation by NMR. Magn Reson Med 1996;35:194-200.
27. Cady EB, editor. Clinical magnetic resonance spectroscopy. New York (NY): Plenum Press; 1990. p. 47-79.
28. Ordidge RJ, Connelly A, Lohman JA. Image selected in vivo spectroscopy (ISIS). A new technique for spatially selective NMR spectroscopy. J Magn Reson 1986;66:283-94.
29. van der Veen JW, de Beer R, Luyten PR, van Ormondt D. Accurate quantification of in vivo 31P NMR signals using the variable projection method and prior knowledge. Magn Reson Med 1988;6:92-8.
30. Stubbs M, Bhujwalla ZM, Tozer GM, Rodrigues LM, Maxwell RJ, Morgan R, et al. An assessment of 31P MRS as a method of measuring pH in rat tumours. NMR Biomed 1992;5:351-9.
31. Bergmeyer HU. Methods of enzymatic analysis. 2nd ed. Weinheim (Germany): Verlag Chemie; 1974. p. 399.
32. Moreno A, Lopez LA, Fabra A, Arus C. 1H MRS markers of tumour growth in intrasplenic tumours and liver metastasis induced by injection of HT-29 cells in nude mice spleen. NMR Biomed 1998;11:93-106.
33. Franks SE, Kuesel AC, Lutz NW, Hull WE. 31P MRS of human tumor cells: effects of culture media and conditions on phospholipid metabolite concentrations. Anticancer Res 1996;16:1365-74.
34. Aiken NR, Gillies RJ. Phosphomonoester metabolism as a function of cell proliferative status and exogenous precursors. Anticancer Res 1996;16: 1393-7.
35. Podo F. Tumour phospholipid metabolism. NMR Biomed 1999; 12:413-39.
36. Li CW, Kuesel AC, Padavic-Shaller KA, Murphy-Boesch J, Eisenberg BL, Schmidt RG, et al. Metabolic characterization of human soft tissue sarcomas in vivo and in vitro using proton-decoupled phosphorus magnetic resonance spectroscopy. Cancer Res 1996;56:2964-72.
37. Gelmon KA, Eisenhauer EA, Harris AL, Ratain MJ, Workman P. Anti-cancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst 1999;91:1281-7.
38. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989;49:6449-65.
39. Jain RK, Carmeliet PF. Vessels of death or life. Sci Am 2001;285:38-45.
40. Negendank W. Studies of human tumors by MRS: a review. NMR Biomed 1992;5:303-24.
41. Govindaraju V, Young K, Maudsley AA. Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed 2000;13:129-53.
42. Negendank WG, Padavic-Shaller KA, Li CW, Murphy-Boesch J, Stoyanova R, Krigel RL, et al. Metabolic characterization of human non-Hodgkin's lymphomas in vivo with the use of proton-decoupled phosphorus magnetic resonance spectroscopy. Cancer Res 1995;55:3286-94.
43. Glaholm J, Leach MO, Collin DJ, Mansi J, Sharp JC, Madden A, et al. In vivo 31P magnetic resonance spectroscopy for monitoring treatment response in breast cancer. Lancet 1989;1:1326-7.
44. de Certaines JD, Larsen VA, Podo F, Carpinelli G, Briot O, Henriksen O. In vivo 31P MRS of experimental tumours. NMR Biomed 1993;6:345-65.
45. Tausch-Treml R, Baumgart F, Ziessow D, Kopf-Maier P. 31P NMR spectroscopy of a xenografted hypopharynx carcinoma: effects of tumor growth and treatment with cisplatin on the tumor phosphorus metabolism, histology and cytokinetics. NMR Biomed 1992;5:127-36.
46. Koutcher JA, Alfieri AA, Devitt ML, Rhee JG, Kornblith AB, Mahmood U, et al. Quantitative changes in tumor metabolism, partial pressure of oxygen, and radiobiological oxygenation status postradiation. Cancer Res 1992;52: 4620-7.
47. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid. metabolism of human mammary epithelial cells. Cancer Res 1999;59:80-4.
48. Ronen SM, Jackson LE, Beloueche M, Leach MO. Magnetic resonance detects changes in phosphocholine correlated with Ras activation and inhibition in NIH 3T3 cells. Br J Cancer 2001;84:691-6.
49. Liu D, Hutchinson OC, Osman S, Price P, Workman P, Aboagye EO. Use of radiolabelled choline as a pharmacodynamic marker for the signal transduction inhibitor geldanamycine. Br J Cancer 2002;87:783-9.
50. Macara IG. Elevated phosphocholine concentration in ras-transformed NIH 3T3 cells arises from increased choline kinase activity, not from phosphatidylcholine breakdown. Mol Cell Biol 1989;9:325-8.
51. Bjorkoy G, Overvatn A, Diaz-Meco MT, Muscat J, Johansen T. Evidence for a bifurcation of the mitogenic signaling pathway activated by Ras and phosphatidylcholine-hydrolyzing phospholipase C. J Biol Chem 1995;270: 21299-306.
52. Lacal JC. Regulation of proliferation and apoptosis by Ras and Rho GTPases through specific phospholipid-dependent signaling. FEBS Lett 1997;410:73-7.
53. van Rossum GS, Klooster R, van den Bosch H, Verkleij AJ, Boonstra J. Phosphorylation of p42/44(MAPK) by various signal transduction pathways activates cytosolic phospholipase A(2) to variable degrees. J Biol Chem 2001;276:28976-83.
54. Ramirez de Molina A, Penalva V, Lucas L, Lacal JC. Regulation of choline kinase activity by Ras proteins involves Ral-GDS and PI3K. Oncogene 2002;21:937-46.
55. Lucas L, Penalva V, Ramirez de Molina A, Del Peso L, Lacal JC. Modulation of phospholipase D by Ras proteins mediated by its effectors Ral-GDS, PI3K and Raf-1. Int J Oncol 2002;21:477-85.